动物用药品市场商机、成长要素、产业趋势分析及2026-2035年预测。

预计到 2025 年，全球动物用药品市场价值将达到 463 亿美元，并有望以 5.8% 的复合年增长率成长，到 2035 年达到 825 亿美元。

动物疾病的增加、人们对畜牧业生产力的日益关注以及全球宠物数量的增长推动了市场成长。随着宠物越来越“拟人化”，宠物饲主对类似于人类医疗的先进医疗保健解决方案的需求不断增长，市场呈现出强劲的发展势头。这一趋势显着增加了对伴侣动物专用治疗药物、预防保健产品和慢性病管理药物的需求。此外，兽医基础设施的不断改进和动物福利意识的提高也进一步加速了市场成长。政府和监管机构在支持动物健康措施和确保有效安全药物的供应方面也发挥着至关重要的作用。

先进动物用药品（包括生物製药和疫苗）的日益普及正在改变产业格局。生物製药因其提供更安全、更具针对性的治疗方案而备受关注，尤其是在牲畜疾病预防和伴侣动物疫苗接种方面。此外，人工智慧驱动的药物研发、远端医疗平台和数位诊断等技术进步正在提高兽医服务的可及性和效率。线上兽药商店和零售分销管道的快速扩张进一步提高了产品的供应量，尤其是在新兴市场。然而，高昂的研发成本、严格的监管要求以及某些药物潜在的副作用等挑战仍然影响着市场动态。儘管存在这些挑战，但预计未来几年对研发和创新的持续投入将创造新的成长机会。

按产品细分，预计2025年，药品市场规模将达248亿美元。此细分市场涵盖了用于治疗和预防伴侣动物和牲畜疾病的各种必需药品，例如感染疾病、驱虫药、抗发炎药和循环系统药物。动物细菌感染疾病、寄生虫疾病和慢性病发病率的不断上升，显着推动了对这些药物的需求。此外，先进製剂和标靶治疗的研发提高了治疗效果和用药依从性。人们对合理使用抗菌药物（AMS）和负责任用药的日益关注，也推动了该领域的创新，促进了更安全、更永续的治疗方案的开发。

预计到2025年，注射剂药物市场将占据主导地位，并在预测期内以5.6%的复合年增长率稳定成长。此细分市场包括肌肉注射、皮下注射和静脉注射的药物。注射药物因其起效迅速、给药精准、疗效可靠而备受青睐，尤其适用于急诊和急性疾病的治疗。肠外给药广泛应用于疫苗、抗生素、止痛药和其他需要即时生物利用度和持续疗效的重要药物。此外，注射剂也适用于缓释製剂、生物製药和无法有效口服的高活性药物，进一步加速了其在医院、诊所和急诊医疗机构的应用。

预计到2025年，北美动物用药品市场规模将达到192亿美元。这主要得益于大规模的牲畜存栏量、较高的宠物饲养率以及先进的兽医医疗基础设施。该地区受益于强有力的监管支持、不断增长的动物保健支出以及兽药领域的持续创新。美国凭藉其庞大的牛数量以及对肉类和乳製品的高需求（这些需求需要有效的疾病管理解决方案），在该市场中扮演着重要角色。此外，兽医服务支出的增加以及预防性医疗保健措施的日益普及也推动了该地区市场的持续成长。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 动物疾病发生率增加
    • 人们对畜牧业生产力越来越感兴趣。
    • 宠物保险的需求正在飙升。
    • 扩大政府对动物福利的措施和支持
    • 研发活动的活性化正在推动兽医学的进步。
    • 拓展线上动物用药品业务
  • 产业潜在风险与挑战
    • 副作用和药品召回
    • 动物用药品研发高成本
  • 市场机会
    • 新兴市场兽医保健基础设施的扩张
    • 预防性兽医学的广泛应用
• 成长潜力分析
• 监理情势（基于初步调查）
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
  • 亚太地区
• 政策环境
• 产品平臺分析（基于初步调查）
• 投资者概览
• 消费者行为趋势（基于初步调查）
• 人工智慧对市场的影响
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
  • 北美洲
  • 欧洲
  • 亚太地区
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估价与预测：依产品划分，2022-2035年

• 製药
  • 驱虫
  • 抗发炎药
  • 抗感染药物
  • 皮质类固醇
  • 镇静剂
  • 循环系统药物
  • 消化器官系统药物
  • 其他药物
• 疫苗
  • 活病毒疫苗（MLV）
  • 灭活疫苗
  • 重组疫苗
• 药用饲料添加剂
  • 抗生素
  • 维他命
  • 胺基酸
  • 酵素
  • 抗氧化剂
  • 益生元和益生菌
  • 矿物
  • 其他药用饲料添加剂

第六章 市场估计与预测：依动物种类划分，2022-2035年

• 伴侣动物
  • 狗
  • 猫
  • 马
  • 其他伴侣动物
• 家畜
  • 家禽
  • 猪
  • 牛
  • 鱼
  • 其他牲畜

第七章 市场估计与预测：依应用领域划分，2022-2035年

• 皮肤科
• 循环系统疾病
• 消化系统疾病
• 呼吸系统疾病
• 其他迹象

第八章 市场估计与预测：依给药途径划分，2022-2035年

• 口服
• 注射药物
• 外用
• 其他给药途径

第九章 市场估价与预测：依通路划分，2022-2035年

• 兽药
• 电子商务
• 零售药房

第十章 市场估价与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 波兰
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 台湾
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 海湾合作委员会国家
  • 以色列

第十一章：公司简介

• Agrolabo SpA
• Boehringer Ingelheim International
• Ceva Sante Animale
• Chanelle Pharma
• Dechra Pharmaceuticals
• Durvet Animal Health Products
• Elanco Animal Health
• Endovac Animal Health
• HIPRA
• Indian Immunologicals
• Merck &Co., Inc.
• Neogen Corporation
• Norbrook
• Vetoquinol
• Virbac
• Zagro
• Zoetis

The Global Animal Drugs Market was valued at USD 46.3 billion in 2025 and is estimated to grow at a CAGR of 5.8% to reach USD 82.5 billion by 2035.

Market growth is driven by the rising prevalence of animal diseases, increasing focus on livestock productivity, and growing pet ownership worldwide. The market is witnessing strong momentum due to the humanization of pets, where owners increasingly demand advanced healthcare solutions like human medicine. This trend has significantly boosted the demand for specialized therapeutics, preventive care products, and chronic disease management drugs for companion animals. Additionally, the expansion of veterinary healthcare infrastructure and increasing awareness about animal welfare are further accelerating market growth. Governments and regulatory bodies are also playing a crucial role by supporting animal health initiatives and ensuring the availability of effective and safe pharmaceutical products.

The increasing adoption of advanced veterinary medicines, including biologics and vaccines, is reshaping the industry landscape. Biologics are gaining traction as they offer safer and more targeted treatment options, particularly for disease prevention in livestock and immunization in companion animals. Moreover, technological advancements such as AI-driven drug discovery, telemedicine platforms, and digital diagnostics are improving accessibility and efficiency in veterinary care. The rapid expansion of online veterinary pharmacies and retail distribution channels is further enhancing product availability, especially in emerging markets. However, challenges such as high development costs, stringent regulatory requirements, and potential adverse effects associated with certain drugs continue to impact market dynamics. Despite these challenges, continuous R&D investments and innovation are expected to create new growth opportunities in the coming years.

Based on product, the drugs segment generated USD 24.8 billion in 2025. This segment includes a wide range of pharmaceuticals such as anti-infectives, antiparasitic drugs, anti-inflammatory agents, and cardiovascular medications that are essential for treating and preventing diseases in both companion and livestock animals. The increasing incidence of bacterial infections, parasitic infestations, and chronic conditions in animals has significantly boosted demand for these drugs. Additionally, the development of advanced formulations and targeted therapies is enhancing treatment effectiveness and compliance. The growing emphasis on antimicrobial stewardship and responsible drug usage is also driving innovation within this segment, encouraging the development of safer and more sustainable treatment options.

The injectable segment held a leading position in the market in 2025 and is projected to experience robust growth at a CAGR of 5.6% during the forecast period. This segment includes medications delivered through intramuscular, subcutaneous, and intravenous administration methods. The injectable route is preferred because it allows for rapid onset of action, accurate dosing, and reliable therapeutic effects, making it particularly suitable for urgent care and acute medical conditions. Parenteral administration is widely utilized for vaccines, antibiotics, analgesics, and other critical medications that demand immediate bioavailability and consistent efficacy. Additionally, the injectable format supports controlled release formulations, biologics, and high-potency drugs that cannot be effectively delivered orally, further driving its adoption across hospitals, clinics, and emergency care settings.

North America Animal Drugs Market reached USD 19.2 billion in 2025, driven by a large livestock population, high pet ownership rates, and advanced veterinary healthcare infrastructure. The region benefits from strong regulatory support, increasing spending on animal healthcare, and continuous innovation in veterinary pharmaceuticals. The U.S. plays a key role due to its large cattle population and significant demand for meat and dairy products, which necessitate effective disease management solutions. Furthermore, rising expenditure on veterinary services and the growing adoption of preventive healthcare measures are contributing to sustained market growth in the region.

Key players operating in the Global Animal Drugs Market include Boehringer Ingelheim, Ceva Sante Animale, Dechra Pharmaceuticals, Elanco Animal Health, Merck & Co., Inc. (MSD Animal Health), Vetoquinol, Virbac, Zoetis, Phibro Animal Health, HIPRA, Norbrook, and Indian Immunologicals. These companies are actively expanding their product portfolios, strengthening their distribution networks, and investing in research and development to maintain their competitive edge. Companies in the Global Animal Drugs Market are adopting several strategic initiatives to strengthen their market position. A key approach is mergers and acquisitions, enabling firms to expand their product portfolios and geographic presence. Companies are also heavily investing in R&D to develop innovative drugs, biologics, and targeted therapies that address evolving animal health needs. Strategic collaborations and partnerships with research institutions and distributors are helping enhance market reach and technological capabilities. Additionally, firms are focusing on digital transformation, including AI-based drug discovery and e-commerce platforms, to improve accessibility and customer engagement. Expansion into emerging markets and strengthening supply chain networks are further supporting long-term growth and competitiveness in the industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Indication trends
  • 2.2.4 Animal type trends
  • 2.2.5 Route of administration trends
  • 2.2.6 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of animal diseases
    • 3.2.1.2 Growing focus on livestock productivity
    • 3.2.1.3 Surging demand for pet insurance policies
    • 3.2.1.4 Growing government initiatives and support towards animal welfare
    • 3.2.1.5 Intensified R&D activities driving advancements in veterinary medicine
    • 3.2.1.6 Expanding online veterinary pharmacies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse side effects and drug recalls
    • 3.2.2.2 High cost associated with animal drugs development
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of veterinary healthcare infrastructure in emerging markets
    • 3.2.3.2 Increasing adoption of preventive veterinary care
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Policy landscape
• 3.6 Product pipeline analysis (Driven by Primary Research)
• 3.7 Investor overview
• 3.8 Consumer behaviour trends (Driven by Primary Research)
• 3.9 Impact of AI on the market
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 Antiparasitic
  • 5.2.2 Anti-inflammatory
  • 5.2.3 Anti-infectives
  • 5.2.4 Corticosteroids
  • 5.2.5 Tranquilizers
  • 5.2.6 Cardiovascular drugs
  • 5.2.7 Gastrointestinal drugs
  • 5.2.8 Other drugs
• 5.3 Vaccines
  • 5.3.1 Modified live vaccines (MLV)
  • 5.3.2 Killed inactivated vaccines
  • 5.3.3 Recombinant vaccines
• 5.4 Medicated feed additives
  • 5.4.1 Antibiotics
  • 5.4.2 Vitamins
  • 5.4.3 Amino acids
  • 5.4.4 Enzymes
  • 5.4.5 Antioxidants
  • 5.4.6 Prebiotics and probiotics
  • 5.4.7 Minerals
  • 5.4.8 Other medicated feed additives

Chapter 6 Market Estimates and Forecast, By Animal Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Companion animals
  • 6.2.1 Dogs
  • 6.2.2 Cats
  • 6.2.3 Horses
  • 6.2.4 Other companion animals
• 6.3 Livestock animals
  • 6.3.1 Poultry
  • 6.3.2 Swine
  • 6.3.3 Cattle
  • 6.3.4 Fish
  • 6.3.5 Other livestock animals

Chapter 7 Market Estimates and Forecast, By Indication, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Dermatology
• 7.3 Cardiovascular diseases
• 7.4 Gastrointestinal diseases
• 7.5 Respiratory diseases
• 7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Injectable
• 8.4 Topical
• 8.5 Other routes of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospital pharmacies
• 9.3 E-commerce
• 9.4 Retail pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Poland
  • 10.3.7 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Taiwan
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 GCC Countries
  • 10.6.3 Israel

Chapter 11 Company Profiles

• 11.1 Agrolabo S.p.A
• 11.2 Boehringer Ingelheim International
• 11.3 Ceva Sante Animale
• 11.4 Chanelle Pharma
• 11.5 Dechra Pharmaceuticals
• 11.6 Durvet Animal Health Products
• 11.7 Elanco Animal Health
• 11.8 Endovac Animal Health
• 11.9 HIPRA
• 11.10 Indian Immunologicals
• 11.11 Merck & Co., Inc.
• 11.12 Neogen Corporation
• 11.13 Norbrook
• 11.14 Vetoquinol
• 11.15 Virbac
• 11.16 Zagro
• 11.17 Zoetis